[Treatment of urticaria with the new H1 antihistaminic astemizole--with special reference to the time of onset of effect and maximum effect].
20 patients, 12 suffering from chronic urticaria, 2 from acute urticaria, 1 from pressure urticaria, 2 from cold urticaria and 3 from urticaria factitia were treated in an open pilot study with the new H1-antihistamine Astemizole. The dosage was in all cases 1 X 10 mg per day. The onset of action as well as the efficacy maximum were registered. Astemizole proved in this study to be a very effective antihistamine being able to achieve good results even in hard to cure cases like cold urticaria. On the 1. day 35% of the patients had noticed an onset of action. 75% of the patients had an onset of action within the first 2 days. The efficacy maximum was achieved within the first 2 days in 60% of the patients.
D000293:Adolescent; D000328:Adult; D000799:Angioedema / Q000188:drug therapy; D016589:Astemizole; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014581:Urticaria / Q000188:drug therapy*
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D016589:Astemizole
Urtikaria-Behandlung mit dem neuen H1-Antihistaminikum Astemizol--Besondere Berücksichtigung des zeitlichen Verlaufes von Wirkungseintritt und Wirkungsmaximum.